Shares of Anthera Pharmaceuticals, Inc. (ANTH) are plunging more than 8% in early trading Monday as cautious StreetSweeper, which calls the biopharmaceutical company “another cash-poor, bubbly biotech about to blow apart”, makes the rounds. The article concludes that based on analyst/doctor’s assessment of “Anthera’s product, blisibimod for lupus, is valueless, and we agree that the stock is virtually the same – worth maybe $1.”
Anthera Pharmaceuticals, Inc. is currently printing a higher than average trading volume with the issue trading 1.2 million shares, compared to the average volume of 1.13M. The stock began trading this morning at $6.14 to currently trade down 44 cents from the prior days close of $6.12. On an intraday basis it gotten as low as $5.56 and as high as $6.16.
On valuation measures, ANTH’s current year EPS growth estimates stand at 18.90% compared to the industry growth rates of 28.90% The name has a most recent quarter price/book ratio of 31.38. EPS for the same period registers at ($1.50).
Anthera’s shares have advanced 145.78% in the last 4 weeks and 220.42% in the past three months. Over the past 5 trading sessions the stock has gained 21.19%. Shares of Anthera Pharmaceuticals, Inc. are up 287.34% this year.
The chart below shows where the equity has traded over the last 52 weeks.